{Reference Type}: Journal Article
{Title}: Availability and geographic access to breast cancer pathology services in Ghana.
{Author}: Price MD;Mali ME;Ernest A;Abrahams AOD;Goold E;Elvira L;Dedey F;Rositch AF;Price RR;Sutherland EK;
{Journal}: PLoS One
{Volume}: 19
{Issue}: 8
{Year}: 2024
{Factor}: 3.752
{DOI}: 10.1371/journal.pone.0305901
{Abstract}: <B>BACKGROUND: </B>Breast cancer poses a significant health challenge in Sub-Saharan Africa, particularly in Ghana, where late-stage diagnoses and limited healthcare access contribute to elevated mortality rates. This study focuses on the crucial role of pathology and laboratory medical (PALM) services in the timely diagnosis of breast cancer within Ghana.<BR><B>METHODS: </B>A cross-sectional survey of hospitals was completed from November 2020 to October 2021, with 94.8% of identified in-country hospitals participating. Pathology service-related parameters assessed included whether pathology was available for the diagnosis of breast cancer on-site or via external referral, the number of pathology personnel, additional breast cancer diagnostic capabilities including estrogen and progesterone and/or HER2 testing, and the time from biopsy to patients receiving their results. Geospatial mapping was used to identify areas of limited access.<BR><B>RESULTS: </B>Of the 328 participating hospitals, 136 (41%) reported breast cancer pathology services, with only 6 having on-site capabilities. Pathology personnel, comprising 15 consultants and 15 specialists, were concentrated in major referral centers, particularly in Greater Accra and Kumasi. An assessment of referral patterns suggested that 75% of the population reside within an hour of breast cancer pathology services. Among the 136 hospitals with access to breast cancer pathology, only a limited number reported that results included ER/PR (38%) and HER2 testing (33%).<BR><B>CONCLUSIONS: </B>Ghana has been able to ensure significant pathology service availability through robust referral pathways with centralized labs. Despite this, difficulties persist with the majority of pathology results not including hormone receptor testing which is important in providing tumor specific treatment.